Helicobacter pylori infection
Conditions
Interventions
Experimental group A:VPZ 20 mg 2/day and Amoxicillin 1g 3/day for 14 days
Experimental group B:JWC160mg 3/day and VPZ 20 mg 2/day and Amoxicillin 1g 3/day for 14 days
Sponsors
Department of Gastroenterology, the First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years; 2. H. pylori (+) determined by C13 or C14; 3. Treatment-naive patients for eradication of H. pylori infection.
Exclusion criteria
Exclusion criteria: 1. Allergy to medications used in this clinical trial; 2. Use of PPI, histamine H2-receptor antagonists, antibiotics, bismuth, probiotics or traditional Chinese medicine 4 weeks before initiating study treatment; 3. Use of adrenocorticosteroids, nonsteroidal anti-inflammatory drugs, and anticoagulants; 4. Alcohol abuse; 5. Presence of diseases or clinical conditions, such as liver disease, cardiac vascular disease,lung disease, kidney disease, metabolic disease, mental illness, or malignant tumors, that might interfere with the evaluation of study treatment; 6. Female patients planning pregnancy, as well as pregnant and breastfeeding patients; 7. Previous esophageal or stomach surgical procedures; 8. Participation in other clinical studies within 3 months before enrollment in this clinical study; 9. Incomplete follow-up or noncompliance with the study treatment; 10. Patients who cannot sign informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hp eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse reactions;Compliance;Relief of the gastrointestinal symptom ; | — |
Countries
China
Contacts
Public ContactXi Chen
Department of Gastroenterology, the First Affiliated Hospital of Anhui Medical University
Outcome results
None listed